Kodiak Sciences Statistics
Total Valuation
Kodiak Sciences has a market cap or net worth of $2.77 billion. The enterprise value is $2.62 billion.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kodiak Sciences has 61.73 million shares outstanding. The number of shares has increased by 1.19% in one year.
| Current Share Class | 61.73M |
| Shares Outstanding | 61.73M |
| Shares Change (YoY) | +1.19% |
| Shares Change (QoQ) | +2.98% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 58.66% |
| Float | 39.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 17.58 |
| P/TBV Ratio | 17.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.72, with a Debt / Equity ratio of 0.38.
| Current Ratio | 4.72 |
| Quick Ratio | 4.61 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -149.49% and return on invested capital (ROIC) is -67.01%.
| Return on Equity (ROE) | -149.49% |
| Return on Assets (ROA) | -42.64% |
| Return on Invested Capital (ROIC) | -67.01% |
| Return on Capital Employed (ROCE) | -76.60% |
| Weighted Average Cost of Capital (WACC) | 17.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.85M |
| Employee Count | 124 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1,802.54% in the last 52 weeks. The beta is 2.40, so Kodiak Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.40 |
| 52-Week Price Change | +1,802.54% |
| 50-Day Moving Average | 29.67 |
| 200-Day Moving Average | 19.70 |
| Relative Strength Index (RSI) | 65.02 |
| Average Volume (20 Days) | 2,075,010 |
Short Selling Information
The latest short interest is 9.85 million, so 15.96% of the outstanding shares have been sold short.
| Short Interest | 9.85M |
| Short Previous Month | 7.05M |
| Short % of Shares Out | 15.96% |
| Short % of Float | 25.21% |
| Short Ratio (days to cover) | 11.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -234.39M |
| Pretax Income | -229.97M |
| Net Income | -229.97M |
| EBITDA | -216.06M |
| EBIT | -234.39M |
| Earnings Per Share (EPS) | -$4.32 |
Full Income StatementBalance Sheet
The company has $209.86 million in cash and $59.18 million in debt, with a net cash position of $150.68 million or $2.44 per share.
| Cash & Cash Equivalents | 209.86M |
| Total Debt | 59.18M |
| Net Cash | 150.68M |
| Net Cash Per Share | $2.44 |
| Equity (Book Value) | 157.38M |
| Book Value Per Share | 2.55 |
| Working Capital | 169.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$136.01 million and capital expenditures -$506,000, giving a free cash flow of -$136.51 million.
| Operating Cash Flow | -136.01M |
| Capital Expenditures | -506,000 |
| Depreciation & Amortization | 18.33M |
| Net Borrowing | n/a |
| Free Cash Flow | -136.51M |
| FCF Per Share | -$2.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kodiak Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.19% |
| Shareholder Yield | -1.19% |
| Earnings Yield | -8.30% |
| FCF Yield | -4.93% |
Analyst Forecast
The average price target for Kodiak Sciences is $35.43, which is -21.09% lower than the current price. The consensus rating is "Buy".
| Price Target | $35.43 |
| Price Target Difference | -21.09% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
